Safety and feasibility study of using Polyphosphate (PolyP) in alveolar cleft repair, A Pilot study.

Salem Alkaabi (al_kaabi33@hotmail.com)
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc
https://orcid.org/0000-0001-9450-6413

Natsir Kalla
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc

Alsabri GA
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc

A Fauzi
Unhas: Universitas Hasanuddin

Jansen NA
VU University Medical Centre Amsterdam: Amsterdam UMC Locatie VUmc

A Tajrin
Unhas: Universitas Hasanuddin

Müller WEG
Mainz University: Johannes Gutenberg Universitat Mainz

HC Schröder
Mainz University: Johannes Gutenberg Universitat Mainz

XH Wang
Universitätsbibliothek Mainz Zentralbibliothek: Johannes Gutenberg Universitat Mainz Universitätsbibliothek Mainz

T Forouzanfar
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc

Helder MN
Amsterdam UMC - Locatie VUMC: Amsterdam UMC Locatie VUmc

M Ruslin
Unhas: Universitas Hasanuddin

Research

Keywords: Polyphosphate, Alveolar bone grafting, Bone regeneration, Regenerative medicine

DOI: https://doi.org/10.21203/rs.3.rs-407486/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Bone grafting is an important surgical procedure to reconstruct alveolar bone defects in patients with cleft lip and palate. Polyphosphate (PolyP) is a physiological polymer present in blood, primarily in platelets. PolyP is playing a role as phosphate source in bone calcium phosphate deposition. Moreover, the cleavage of high-energy bonds to release phosphates provides local energy necessary for regenerative processes. In this study, polyP is complexed with calcium to form Calcium polyP microparticles (Ca-polyP MPs), which were shown to have osteoinductive properties in preclinical studies. The aim of this study was to evaluate the feasibility, safety and osteoinductivity of Ca-polyP MPs in-first human clinical trial.

**Methods:** This single blinded, randomized, prospective clinical pilot study enrolled eight adolescent patients (mean age 18.1: range 13 - 34 years) with residual alveolar bone cleft. Randomization in two groups (four receiving Ca-polyP MPs only, four a combination of Ca-polyP MPs and biphasic calcium phosphate (BCP)) was performed. Patient follow-up was six months. Outcome parameters included safety parameters and close monitoring of possible adverse effects using radiographic imaging, regular blood tests, and physical examinations.

**Results:** Due to surgical and technical reasons, eventually only 2 patients received Ca-polyP MPs, and the others the combination graft. All patients were assessed up to day 90. Four out of eight were able to continue with the final assessment day (day180). Three out eight were unable to reach the hospital due to Covid-19 restrictions. One patient decided not to continue with the study.

No allergies or remarkable local or systematic reaction were noticed in all patients. Radiographically, patients receiving Ca-polyP MPs only were scored grade IV Bergland scale, while patients received combination Ca-polyP MPs and BCP were ranged from score I to III.

**Conclusions:** Ca-polyP MPs and combination of Ca-polyP MPs/BCP are safe graft materials, however, Ca-polyP MPs alone are not sufficiently stable defect-filling scaffolds to be used in alveolar cleft repair.

**Trial registration:** Indonesian Trial Registry under number INA-EW74C1N by the ethical committee of Faculty of Medicine, Hasanuddin University, Makassar, Indonesia with code number 1063/UN4.6.4.5.31/PP36/2019

Introduction

**Background**

Cleft lip and palate (CLP) are common anomalies in craniofacial region and considered as the second most common congenital deformity after the clubfoot(1). An alveolar cleft is seen in 75% of the CLP patients (2,3). Alveolar bone grafting (ABG) is an essential functional and esthetic procedure to reconstruct the bony defect in the maxilla as well as the nasal floor (4). ABG not only plays an important role to facilitate teeth eruption, but also to fill the bony defect by closing the oronasal fistula that routinely occurs in alveolar cleft patients.

The alveolar bone grafting can be performed either by using autogenous bone, allograft bone, or bone substitutes. Autogenous bone graft is still considered as the gold standard for any grafting procedure (5), nevertheless, numerous studies are employing various bone substitutes or allografts to overcome the risks and complications that could raise from harvesting bone at the donor site (6,7,8). Risks such as gait disturbance, hematoma, donor site morbidity and other concerns that are associated with the growth (through harvesting from the rib or the iliac crest), could be avoided if having a good allograft or bone substitute material (9).

Polyphosphate (polyP) is a molecule that is naturally present in platelets in the blood stream. Müller and his colleagues have been able to structure a new graft material by precipitation of polyP with calcium, thus forming Ca-polyP microparticles (Ca-polyP MPs) (10, 11, 12). The Ca-polyP MPs were proven to have bone osteoinductive characteristics in preclinical studies (12, 13, 14). It has been shown that the Ca-polyP MPs can accumulate and concentrate at the site of the new bone formation. PolyP polymer elicits both the anabolic signals and the fuels due to energy-rich phosphate anhydrides linkages as well as the metabolic process in the cells. Such signals could accelerate the cell growth and differentiation (15).
On the other hand, Biphasic calcium phosphate (BCP) is another type of graft that contain a phosphate molecule mixed with Hydroxyapatite (HA) in different ratios. Different specification outcomes have been reported to the BCP as graft material, some stated that the BCP has osteoconductive characteristic (16, 17), while others concluded that it also can be osteinductive in nature (18, 19).

**Objective**

This first-in-human study aims to evaluate the safety and feasibility of Ca-polyP MPs as a graft material in alveolar cleft patients.

**Material And Methods**

**Ethics**

This single blinded, randomized, prospective clinical trial, a pilot study, was approved by the ethical committee of Faculty of Medicine, Hasanuddin University, Makassar, Indonesia with code number 1063/UN4.6.4.5.31/PP36/2019. It was registered in the Indonesian Trial Registry under number INA-EW74C1N. The study protocol complies with the principles of the Helsinki declaration. Participants and legal guardians of the patients signed an informed consent.

**Patients and randomization:**

This study enrolled eight patients with residual alveolar bone cleft. The inclusion criteria's were; non-syndromic, nonsmoker, age of ≥ 13, no history of previous grafting procedure(s) and ASA1 regarding anesthetic risks. The exclusion criteria's were; systemic diseases, syndromic patients, localized infection, active influenza, obvious malnutrition or patient under any active medical treatment. Randomly, four out of eight patients were selected to receive the Ca-polyP MPs alone, while the other four patients were to receive a mixture of Ca-polyP MPs and BCP as a graft material. However (see results) eventually two patients only received Ca-polyP MPs alone, while six received the mixture. The surgeon and the patients were revealed to the graft type, nevertheless, the assessor was kept completely blinded from the patient grouping. The time schedule of the surgical procedure and follow-up moments is presented in (Table 1).

**Sample size**

Since this is a first-in-man trial, the number of patients were kept low in order to minimize the risk of the graft exposure in case of any adverse effect. The current trial sample were limited to only 2x4 patients, with the primary goal to gain a first insight on the feasibility and safety of the treatment with polyp.

**Randomization and treatment allocation**

It was not possible to keep all patients blinded to assessment group due to the nature of this trial as first in human study. After written informed consent, randomization was performed with regard to the treatment group, but the patients were kept aware of the fact that they will be treated with Ca-polyP MPs.

**Blinding**

The radiologist remained blind to the treatment when evaluating the data.

**Data collection**

Doctors, nurses and rest of the research team were provided with a list of rules and responsibilities. The doctors and nurses collected the data according to the assessment Table 1. All research team members received training on how to collect data at all study visits. Each patient has been followed up to 6 months. Participant confidentiality was protected by the data manager.

**Point:**

N/A no additional consent is required at this level of the trial.
Polyp and BCP preparation:

PolyP graft comes in a form of Ca-polyP MPs powder produced by NanotecMARIN GmbH (Mainz, Germany), while the BCP consists of a mixture of 60% hydroxyapatite and 40% of beta-tricalcium phosphate (Straumann Bone Ceramic, Villeret, Switzerland). Under sterile conditions, either Ca-polyP MPs or a mixture of Ca-polyP MPs and BCP was prepared using normal saline or blood at a ratio of 1g: 1.5 ml and 1g:2g:3-5 ml respectively. The components were mixed until a homogenous mixture was obtained (Figure 1).

Surgical procedure:

Under general anesthesia and full aseptic conditions, the oral cavity was rinsed with 0.1% chlorhexidine gluconate solution. A local anesthesia infiltration using lidocaine with epinephrine 1:100,000 was given. Full mucoperiosteal flap was reflected from first molar to the central incisor on the contralateral side of the defect. The tissue was dissected carefully to separate the oral mucosa from the nasal layer. A palatal mucoperiosteal flap was reflected from either side of the cleft followed by elevation of the palatal tissues. The nasal mucosa was cranially elevated and sutured cranially to repair the oro-nasal fistula (Figure 2a). A Ca-polyP MPs preparation or the Ca-polyP MPs and BCP mixture was applied into the alveolar cleft defect (Figure 2b). Tension free closure was realized in all wounds.

Post-operative care:

Oral hygiene instructions were given to all patients including mouth rinsing with 0.12% Chlorhexidine. Proper antibiotics and pain killers were prescribed for 7 days. During hospital stay, follow-up examinations of all patients were meticulously performed to report any adverse reaction to the grafting materials locally or systemically. After patient discharge, all patients followed an assessment timetable.

Orthopantomogram (OPG):

Bergland scale.

OPGs were taken one day preoperatively (X-Mind Pano D+ Satelec- Digital panoramic with teleradiography - Satelec), and then subsequently after 8, 30, 90 and 180 days. The OPGs were used to assess the vertical graft formation employing the Bergland scale, which is the gold standard used to evaluate the integrity and height of the alveolar bone graft (20). The Bergland scale is classified into four grades; grade I: bone height is almost a normal height, grade II: a bone height at least 75% of interalveolar septum, grade III: the bone height is less than 75%, grade IV: no evidence of bone integration (21).

CT scan:

The CT scans (Siemens SOMATOM Definition Flash CT Scanner) were performed pre-operatively, and at postoperative days 8 and 180. The data were processed by OsiriX (Pixmeo, Switzerland), an open-source Digital Imaging and Communications in Medicine (DICOM).

Results

All patients were able to comply with the study requirements up to assessment day 90. Unfortunately, four out of eight patients were unable to continue with the final assessment (day 180). One patient decided not to continue with the study, while the other three patients were unable to approach the hospital due to the Covid-19 lockdown at their towns/villages (Table 2).

All eight patients underwent bone grafting surgery by the same surgeon. There were no reported postoperative complications, local or systematic, in both study groups. All patients were in close follow-up from day 1 until they were discharged from hospital (day 3). Thereafter, the patients were followed up according to Table 2.

Safety:

Adverse events
The main goal of this study was to evaluate the safety of the Ca-polyP MPs, alone or in combination with BCP, in terms of adverse events (local or systematic) using clinical assessment, radiographic, and laboratory investigations (a.o. white blood cells, neutrophil, lymphocyte, and if needed C-reactive protein) (Table 3). All patients were kept hospitalized postoperatively for 72 hours to maintain close follow-up.

**Radiographic evaluation:**

**Orthopantomogram:**

The Bergland scale was used in this study to investigate the result of the secondary bone grafts in alveolar defects. This scale is considered the gold standard to assess the post alveolar graft height of the interdental septum. Although OPG is more susceptible to distortions, it was chosen because it is more patient-friendly when compared to the other intra-oral x-rays, especially when taken postoperatively.

In the Ca-polyP MPs group (patients 1 and 2), bone levels were not suitable to be analyzed with the Bergland scale, and we decided to score them as grade IV bone level at all assessment days (Table 4). One of these patients could not attend the last follow-up session (day 180). In the Ca-polyP MPs-BCP group, the bone level ranged from grade I to III in assessment day 1, 8 and 90. Only three patients could be assessed at day 180 and all of them had grade III bone level (Table 4).

**CT scan evaluation:**

As indicated above, the bone levels in the Ca-polyP MPs group could not be analyzed with the Bergland scale. The material had a ground glass appearance (scattered light radiopaque). Since no bone level could be identified we classified them as grade IV at both day 8 and day 180. Likewise in the Ca-polyP MPs-BCP group, the CT scans showed a differential bone level from grade I to grade III per patient (Table 5). For the last three patients who could be scanned at day 180, bone levels were found to be coinciding with those of the OPG, grade III Bergland scale.

**Complications:**

There were no complications reported intra- and/or post-operatively in both study groups.

**Discussion**

In the current trial we found that Ca-polyP MPs is a safe and feasible material: no unusual adverse reactions were reported, such as infection, severe pain, swelling, allergic reaction, or any other local or systemic adverse effects.

The optimum age for the alveolar bone grafting is considered to between 9 -11 years old (20, 22). Since we did not want to enroll children in a safety study with this novel material in clinical practice, we chose to only include older adolescent and adult patients, being capable themselves to be involved in decision making. We performed this study in Indonesia, because non-operated patients in this age group are difficult to find in Europe.

In the Ca-polyP MPs group, the main challenge was in the handling and application of the material in the alveolar defect. The characteristics of the Ca-polyP MPs can be determined by Pi: Ca+2 molar ratio. In our trial we used a paste-like mixture formed by mixing fine Ca-polyP MPs graft with normal saline as described in the materials and methods. However, the resulting Ca-polyP MPs graft material was easily lost from the surgical sites once it got saturated with blood, which made maintaining a space-occupying scaffold within the alveolar defect virtually impossible. We therefore had to conclude that the physical characteristics of the Ca-polyP MPs used as a stand-alone scaffold material were insufficient and unfeasible. As a consequence, we had to reduce the Ca-polyP MPs only group to 2 patients instead of 4 patients as planned originally in the study protocol. Retrospectively, the reason that the microparticles were previously shown to be effective in bone formation in preclinical studies may be due to the location used: it was implanted in a subcutaneous pocket instead of a not well contained, large void such as the alveolar cleft (23, 24).
Combining the Ca-polyP MPs with BCP considerably improved the consistency, ease of handling, stability of the graft, and clinical outcome. BCP and calcium phosphates in general have been used as a graft material several times in craniofacial surgery before. For example, Levitt et al. had already used calcium phosphate in 1969 for this purpose, and calcium phosphates were subsequently used in dental implant, alveolar ridge augmentation, periodontal treatment and other maxillofacial surgeries. Biphasic calcium phosphate (BCP) has been proven to be biocompatible and exhibit osteoconductive as well as osteoinductive characteristics in bony defects reconstruction(16, 17, 19), and calcium phosphate was also recently applied in alveolar cleft surgery (25). Based on our results, we recommend that the bioactive polyP should be combined with a stable carrier such as BCP or bioresorbable polymers to ensure proper reconstructive activity. Likely, special attention should be paid to sequestration of the polyP on or within the carrier, of which we could not be sure in the current study.

Our study was limited by several aspects, the most severe being the COVID-19 pandemic allowing only 4 patients to be evaluated after 180 days of follow-up and thereby resulting in a rather short postoperative follow-up period. Another limitation was the rather radiolucent characteristic of the Ca-polyP MPs, which hampered visualization of the graft in radiographic images considerably and making evaluation with the Bergland scale virtually impossible. We also tried the Chelsea scale, but that also was unsuccessful. We can therefore not be completely sure whether defect filling was sufficient and if some initial bone regeneration events occurred, but at least no solid bone formation was demonstrated after 3 months, and also not in the one patient evaluated after 6 months. Last but not least, it may be that the choice to include only adolescent and adult people in our study and to exclude prepuberal children may have affected the efficacy of the treatment. Bone formation activity usually has its highest peak during puberty, and our post-puberal patient population may therefore have more restricted bone formation capacity per se. In addition, the cleft defects in our patients were mostly rather large, thus reducing the likeliness of effective bone regeneration as well.

To our knowledge, this study is the first clinical trial to investigate the safety and feasibility of polyP, either as Ca-polyP MPs alone or in combination with BCP in humans. Despite the limitations listed above, we can conclude that both formulations appear to be safe materials for use in alveolar cleft surgery. However, due to the COVID-19 pandemic the number of patients that could be followed up for longer than 3 months was rather low, and evaluation of bone formation through histological and histomorphometric analysis of bone biopsies had to be abandoned. Therefore, new studies with a larger group of patients, biopsy evaluations, and suitable polyP formulations encompassing appropriate carriers such as BCPs or polymeric scaffold materials are required for sound conclusions about its regenerative capacities. Also, now safety appears not to be an issue, also younger patients commonly subjected to alveolar cleft reconstructions may be considered.

**Conclusions**

Despite the small sample group size and some missing data points due to the COVID-19 pandemic, we were able to conclude that Ca-polyP MPs and the Ca-polyP MP/BCP composites are safe graft materials, however, Ca-polyP MPs alone are not sufficiently stable defect-filling scaffolds to be used in alveolar cleft repair.

**List Of Abbreviations**

- **PolyP**: Polyphosphate
- **Ca-polyP MPs**: Calcium polyP microparticles
- **BCP**: Biphasic calcium phosphate
- **CLP**: Cleft lip and palate
- **ABG**: Alveolar bone grafting
- **HA**: Hydroxyapatite

**Declarations**
Ethical Approval and Consent to participate

The trial protocol has been evaluated by the Ethical Committee of Faculty of Medicine, Hasanuddin University, Makassar, Indonesia has approved the trial with code number 1063/UN4.6.4.5.31/PP36/2019.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Availability of supporting data

Availability of data and materials: Original data is stored securely within the, Hasanuddin University, Makassar, Indonesia. Scored date as well as output for analyses are available upon request from the study.

Competing interests

This article is free of conflict of interest and no funding was received.

Funding

WEGM and HCS are owners of NanotecMARIN GmbH, Mainz, Germany, and the provider to the polyP graft materials for the clinical trial. SAA received a scholarship from the ministry of health of the UAE. DSNK received a scholarship of the LPDP of Indonesia. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could affect the study result or any other potential of interest.

Authors' contributions

Alkaabi SA & Natsir Kalla DS: Main author and Conceptualization and Writing.:
Ruslin M: Correspondance.
Alsabri GA & Jansen NA: Reviewer and editing.
Ruslin M, Fauzi A & Tajrin A: Surgical procedures.
Müller WEG, Schröder HC & Wang XG: PolyP Inventor.
Forouzanfar T& Helder MN: Methodology and supervision.

Authors's information

Alkaabi SA, Natsir Kalla DS, Alsabri GA, Jansen NA, Forouzanfar T & Helder MN: Dept. of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam University Medical Centers and Academic Centre for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands.
Ruslin M, Fauzi A & Tajrin A: Dept. of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hasanuddin University, Makassar, Indonesia. Role: Surgical procedures. Müller WEG, Schröder HC & Wang XG: Institut für Physiologische Chemie, Angewandte Molekularbiologie, Universitätsmedizin, Johannes Gutenberg-Universität Mainz, Mainz, Germany.

Acknowledgements

Not applicable.

References
1. Sulik KK. Caniofacial development. In: Turvey TA, Vig KWL, editors. Facial clefts and craniosynostosis and principles and management. Philadelphia: WB Saunders Company. 1996;3-27.

2. Seifeldin SA. Is alveolar cleft reconstruction still controversial? (Review of literature). Saudi Dent J. 2016;28(1):3-11.

3. Cho-Lee GY, García-Díez EM, Nunes RA, Martí-Pagès C, Sieira-Gil R, Rivera-Baró A Ann. Review of secondary alveolar cleft repair. Maxillofac Surg. 2013; 3(1):46-50.

4. Abyholm, FE, Bergland O, Semb G. Secondary bone grafting of alveolar clefts. A surgical/orthodontic treatment enabling a non-prosthetic rehabilitation in cleft lip and palate patients. Scand. J. Plast. Reconstr. Surg. 1981;15,127–140.

5. Sakamoto Y, Sakamoto T, Ishii T, Kishi K. Assessment of Bioabsorbable Hydroxyapatite for Secondary Bone Grafting in Unilateral Alveolar Clefts. Cleft Palate Craniofac J.2020;57(1):114-117.

6. Al-hamady HH, Abd Elazeem AF, Bellah Ahmed NE, Shawkat WM, Elmasry M, Abdelrahman MA, Abderazik MA. Combining autologous bone marrow mononuclear cells seeded on collagen sponge with Nano Hydroxyapatite, and platelet-rich fibrin: Reporting a novel strategy for alveolar cleft bone regeneration. J Craniomaxillofac Surg. 2018;46(9):1593-1600.

7. Du F, Wu H, Li H, Cai L, Wang Q, Liu X, Xiao R, Yin N, Cao Y. Bone Marrow Mononuclear Cells Combined with Beta-Tricalcium Phosphate Granules for Alveolar Cleft Repair: A 12-Month Clinical Study. Sci Rep.2017,23,7(1):13773.

8. Sadove AM, Nelson CL, Eppley BL, Nguyen B. An evaluation of calvarial and iliac donor sites in alveolar cleft grafting. Cleft Palate J. 1990; 27(3):225-8.

9. Müller WEG, Achermann M, Wang S, Neufurth M, Muñoz-Espi R, et al. Inorganic polyphosphate induces accelerated tube formation of HUVEC endothelial cells. Cell. Mol. Life Sci. 2013;75: 21-32.

10. Müller WEG, Neufurth M, Wang S, Ackermann M, Muñoz-Espi R, et al. Amorphous, Smart, and Bioinspired Polyphosphate Nano/Microparticles: A Biomaterial for Regeneration and Repair of Osteo-Articular Impairments In-Situ. Int J Mol Sci. 2018;31:19(2). pii: E427.

11. Müller WEG, Wang XH, Diehl-Seifert B, Kropf K, Schloßmacher U, et al. Inorganic polymeric phosphate/polyphosphate as an inducer of alkaline phosphatase and a modulator of intracellular Ca2+ level in osteoblasts (SaOS-2 cells) in vitro. Acta Biomater. 2011;7:2661-2671.

12. Wang XH, Schröder HC, Müller WEG. Amorphous polyphosphate, a smart bioinspired nano-/bio-material for bone and cartilage regeneration: towards a new paradigm in tissue engineering. J. Mat Chem B. 2018;6:2385-2412.

13. Müller WE, Schröder HC, Tolba E, Diehl-Seifert B, Wang X. Mineralization of bone-related SaOS-2 cells under physiologic hypoxic conditions. FEBS J. 2016: 283(1):74-87.

14. Miron RJ, Sculean A, Shuang Y, Bosshardt DD, Gruber R, Buser D, Chandad F, Zhang Y. Osteoinductive potential of a novel biphasic calcium phosphate bone graft in comparison with autographs, xenografts, and DFDBA. Clin Oral Implants Res. 2016;27(6):668-75.

15. Manjubala I, Sastry TP, Kumar RV. Bone in-growth induced by biphasic calcium phosphate ceramic in femoral defect of dogs. J Biomat Appl. 2005; 19(4):341-60.

16. Kawakami S, Hiura K, Yokozeki M, Seike T, Nakanishi H, Moriyama K. Prognostic implications of nasal cavity and cleft morphology in secondary bone grafting. Cleft Palate Craniofac J. 2002;39:575-81.

17. Semb G. Effects of alveolar bone grafting on maxillary growth in unilateral cleft lip and palate patients. Cleft Palate J. 1988;25:288-295.

18. Müller WEG, Tolba E, Schröder HC, Neufurth M, Wang S, Link T, Al-Nawas B and Wang XH. A new printable and durable N,O-carboxymethyl chitosan-Ca2+-polyphosphate complex with morphogenetic activity. J. Mat. Chem B. 2015;3:1722-1730.

19. Wang XH, Wang S, He, Tolba E, Schröder HC, Diehl-Seifert B, Müller WEG. Polyphosphate as a Bioactive and Biodegradable Implant Material: Induction of Bone Regeneration in Rats. ADVANCED ENGINEERING MATERIALS. 2016:8:1406-1417.

20. De Ruiter A, Janssen N, van Es R, Frank M, Meijer G, Koole R, Rosenberg T. Micro-structured Beta-Tricalcium Phosphate for Repair of the Alveolar Cleft in Cleft Lip and Palate Patients: A Pilot Study.Cleft Palate Craniofac J. 2015;52(3):336-40.

Tables
Table 1: Treatment time schedule:

|                      | Consent form | Panorama | CBCT or CT | Physical examination | CBC | Thermometer | Biopsy |
|----------------------|--------------|----------|------------|----------------------|-----|-------------|--------|
| Preoperatively       | ✓            | ✓        | ✓          | ✓                    | ✓   | ✓           | ✓      |
| Operative day        |              |          |            |                      | ✓   |             |        |
| Post-op day 1        | ✓            |          |            |                      | ✓   |             |        |
| Post-op day 8        | ✓            | ✓        |            |                      | ✓   |             |        |
| Post-op day 14       |              |          |            |                      | ✓   |             |        |
| Post-op day 30       |              |          |            |                      | ✓   |             | ✓      |
| Post-op day 90       |              |          |            |                      | ✓   |             | ✓      |
| Post-op day 180      |              | ✓        |            |                      | ✓   |             | ✓      |

OPG: Orthopantomogram; CT: computed tomography; CBCT: Cone Beam CT

Table 2: Demographic and assessment data:

|       | Pt.1       | Pt.2       | Pt.3       | Pt.4       | Pt.5       | Pt.6       | Pt.7       | Pt.8       |
|-------|------------|------------|------------|------------|------------|------------|------------|------------|
| Gender| F          | F          | M          | F          | F          | F          | F          | F          |
| Age   | 18         | 13/14      | 13         | 15         | 13         | 15         | 24         | 34         |
| Affected side | Left     | Left       | Bilateral  | Left       | Right      | Left       | Right      | Left       |
| Graft type | Ca-polyP MPs | Ca-polyP MPs | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP |
| Assessment day 30 | Completed | Completed | Completed | Completed | Completed | Completed | Completed | Completed |
| Assessment day 90 | Completed | Completed | Completed | Completed | Completed | Completed | Completed | Completed |
| Assessment day 180 | Missed follow-up, Covid-19 lockdown | Completed | Completed | Completed | Missed follow-up, Covid-19 lockdown | Missed follow-up, Covid-19 lockdown | Drop-out | Completed |

Pt.: patient; F: female; M: male; Ca-polyP: Calcium polyphosphate microparticles; BCP: biphasic calcium phosphate

Table 3: Safety assessments:
| Graft type               | Pt.1       | Pt.2       | Pt.3       | Pt.4       | Pt.5       | Pt.6       | Pt.7       | Pt.8       |
|-------------------------|------------|------------|------------|------------|------------|------------|------------|------------|
| Ca-polyP MPs            | Ca-polyP MPs | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP | Ca-polyP MPs + BCP |
| Pain                    | Mild       | Mild       | Minimum pain/pressure | Mild       | Mild       | Minimum pain/pressure | Mild       | Moderate   |
| Fever                   | No         | No         | No         | No         | No         | No         | No         | No         |
| Allergic reaction       | ND         | ND         | ND         | ND         | ND         | ND         | ND         | ND         |
| Remarkable local        | No         | No         | No         | No         | No         | No         | No         | No         |
| inflammation/infection  | ND         | ND         | ND         | ND         | ND         | ND         | ND         | ND         |
| Systematic adverse      | ND         | ND         | ND         | ND         | ND         | ND         | ND         | ND         |
| adverse effect          |            |            |            |            |            |            |            |            |
| Lab tests               | Within normal limits | Within normal limits | Within normal limits | Within normal limits | Within normal limits | Within normal limits | Within normal limits |

Ca-polyP MPs: Calcium polyphosphate microparticles, BCP; Biphasic calcium phosphate, ND; nothing detected

Table 4: Bergland scores based on OPGs:

| Bergland scale | Ca-PolyP MPs graft | Ca-PolyP MPs + BCP |
|----------------|-------------------|--------------------|
|                | Pt.1   | Pt.2   | Pt.3   | Pt.4   | Pt.5   | Pt.6   | Pt.7   | Pt.8   |
| Day 1          | IV     | IV     | I      | I      | I      | I      | I      | I      |
| Day 8          | IV     | IV     | I      | I      | I      | I      | I      | I      |
| Day 90         | IV     | IV     | III    | III    | III    | III    | III    | III    |
| Day 180        | ND     | IV     | III    | III    | ND     | ND     | ND     | III    |

ND: No data

Table 5: Bergland scores based on CTs scan:

| Bergland scale | Ca-polyP MPs graft | Ca-polyP MPs + BCP |
|----------------|-------------------|--------------------|
|                | Pt.1   | Pt.2   | Pt.3   | Pt.4   | Pt.5   | Pt.6   | Pt.7   | Pt.8   |
| Day 8          | IV     | IV     | I      | II     | I      | III    | I      | II     |
| Day 180        | Missed follow-up, | IV     | III    | III    | Missed follow-up, | IV     | III    | Missed follow-up, | Drop- |
| Covid-19 lockdown|       |       |       |       | Covid-19 lockdown|       |       | Covid-19 lockdown| out |

a-polyP MPs: Calcium polyphosphate microparticles, BCP; Biphasic calcium phosphate

Figures
Figure 1

Ca-polyP MP + BCP mixed with normal saline.

Figure 2

a: Nasal floor reconstruction and exposing the bony edges, b: Ca-polyP graft placed in the defect.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- PRISMA2020abstractchecklist.docx